HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Derrick Gingery

Senior Writer

Washington, DC

Derrick focuses on the US FDA user fee programs, regulations and policy for new and generic drugs, biologics and biosimilars, advisory committee and other agency activities, as well as federal legislation and budget matters on Capitol Hill. He also hosts Pink Sheet's Pharma Regulatory Podcast. An award-winning journalist, Derrick has been a reporter for several community newspapers and a business journal. When not following FDA, Derrick is keeping close tabs on Indiana University basketball.

Latest From Derrick Gingery

US FDA Says Confirmatory Trials Should Start Before Accelerated Approval But Is Not ‘Dogmatic’

Beginning confirmatory trials before the accelerated approval is granted shortens the time between clearance and the confirmation of benefit, when patients are at risk, said Oncology Center of Excellence Director Richard Pazdur.

Clinical Trials Review Pathway

Could US FDA Move Gene Therapy Regulation To Device Center In Years To Come?

CBER Director Peter Marks said more sophisticated manufacturing expected in the next decade could lead to questions about whether gene therapies should be regulated by his center or CDRH.

Gene Therapy Manufacturing

US FDA Implementing Hybrid Work Policy In January

Agency employees will have on-site, telework and remote possibilities, but options will depend on the center, office and job duties.

FDA Coronavirus COVID-19

Generic Sample Access Process For REMS-Protected Brands Now Includes Agency Timeline

US FDA has 120 days to review generic sponsors’ requests for letters to help them obtain product samples, but will not send them to the reference product company.

Generic Drugs Research & Development

US FDA Implementing Hybrid Work Policy In January

Agency employees will have on-site, telework and remote possibilities, but options will depend on the center, office and job duties.

FDA Coronavirus COVID-19

US FDA Implementing Hybrid Work Policy In January

Agency employees will have on-site, telework and remote possibilities, but options will depend on the center, office and job duties.

FDA Coronavirus COVID-19
See All
UsernamePublicRestriction

Register